Mereo BioPharma (MREO) Retained Earnings (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Retained Earnings of $551.0 million for Q1 2026, up 1.24% year-over-year from $544.3 million in Q1 2025, and little changed quarter-over-quarter from $549.6 million in Q4 2025.
Mereo BioPharma (MREO) Retained Earnings (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Retained Earnings for 10 consecutive years, with $551.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 1.24% year-over-year to $551.0 million; the TTM figure through Mar 2026 stood at $551.0 million (up 1.24% YoY), while the FY2025 annual figure was $549.6 million, up 1.85% from the prior year.
- Retained Earnings was little changed at $551.0 million in Q1 2026 per MREO's latest filing, from $549.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $551.0 million in Q1 2026 and bottomed at -$428.2 million in Q2 2023.
- Historically, Retained Earnings has averaged $359.5 million across 5 years, with a median of $536.4 million in 2024.
- On a YoY basis, Retained Earnings climbed as much as 225.15% in 2023 and fell as far as 357.08% in 2023.
- Mereo BioPharma's Retained Earnings stood at -$388.4 million in 2022, then surged by 225.15% to $486.1 million in 2023, then grew by 11.01% to $539.6 million in 2024, then rose by 1.85% to $549.6 million in 2025, then increased by 0.25% to $551.0 million in 2026.
- Business Quant data shows MREO's Retained Earnings at $551.0 million in Q1 2026, $549.6 million in Q4 2025, and $548.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 552.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 552.34 Mn |
| Mar 31, 2026 | 551.02 Mn |
| Dec 31, 2025 | 549.62 Mn |
| Sep 30, 2025 | 548.04 Mn |
| Jun 30, 2025 | 546.33 Mn |
| Mar 31, 2025 | 544.27 Mn |
| Dec 31, 2024 | 539.64 Mn |
| Sep 30, 2024 | 536.43 Mn |
| Jun 30, 2024 | 534.73 Mn |
| Mar 31, 2024 | 486.93 Mn |
| Dec 31, 2023 | 486.11 Mn |
| Jun 30, 2023 | -428.21 Mn |
| Dec 31, 2022 | -388.43 Mn |
| Jun 30, 2022 | 166.57 Mn |
| Dec 31, 2021 | 175.02 Mn |
| Jun 30, 2021 | 181.74 Mn |
| Dec 31, 2020 | -408.93 Mn |
| Jun 30, 2020 | 158.60 Mn |
| Dec 31, 2019 | 76.05 Mn |
| Jun 30, 2019 | -163.82 Mn |